当前位置: X-MOL 学术Lancet Respir. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Aptamer-based proteomic profiling for prognostication in pulmonary arterial hypertension
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2017-06-14 , DOI: 10.1016/s2213-2600(17)30209-6
Evangelos Giannitsis , Matthias Mueller-Hennessen , Hugo A Katus

Despite the advances in risk assessment and therapy that have improved morbidity and mortality, pulmonary arterial hypertension still remains a devastating disease with high mortality.1 Therefore, precise prognostic stratification of patients with severe pulmonary arterial hypertension is of paramount importance. Most prognostic markers recommended by the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) guidelines1 are related to right ventricular function and cardiac output, including various indices of exercise tolerance, mean right atrial pressure, and cardiac index.


中文翻译:

基于适体的蛋白质组学分析在肺动脉高压中的预后



尽管风险评估和治疗方面的进展已经改善了发病率和死亡率,但是肺动脉高压仍然是具有高死亡率的毁灭性疾病。1因此,对重度肺动脉高压患者进行精确的预后分层至关重要。欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)指南1推荐的大多数预后指标均与右心室功能和心输出量有关,包括运动耐量,平均右心房压力和心脏指数的各种指标。
更新日期:2017-08-10
down
wechat
bug